Kato M, Putta S, Wang M et al.TGF-beta activates Akt kinase through a microRNA-dependent amplifying circuit targeting PTEN. Nat Cell Biol 11:881-889

Gonda Diabetes Center, Beckman Research Institute of the City of Hope, Duarte, CA 91010, USA.
Nature Cell Biology (Impact Factor: 19.68). 07/2009; 11(7):881-9. DOI: 10.1038/ncb1897
Source: PubMed


Akt kinase is activated by transforming growth factor-beta1 (TGF-beta) in diabetic kidneys, and has important roles in fibrosis, hypertrophy and cell survival in glomerular mesangial cells. However, the mechanisms of Akt activation by TGF-beta are not fully understood. Here we show that TGF-beta activates Akt in glomerular mesangial cells by inducing the microRNAs (miRNAs) miR-216a and miR-217, both of which target PTEN (phosphatase and tensin homologue), an inhibitor of Akt activation. These miRNAs are located within the second intron of a non-coding RNA (RP23-298H6.1-001). The RP23 promoter was activated by TGF-beta and miR-192 through E-box-regulated mechanisms, as shown previously. Akt activation by these miRs led to glomerular mesangial cell survival and hypertrophy, which were similar to the effects of activation by TGF-beta. These studies reveal a mechanism of Akt activation through PTEN downregulation by two miRs, which are regulated by upstream miR-192 and TGF-beta. Due to the diversity of PTEN function, this miR-amplifying circuit may have key roles, not only in kidney disorders, but also in other diseases.

Download full-text


Available from: Mitsuo Kato, Oct 04, 2015
1,379 Reads
  • Source
    • "Results in this study support the conclusion that miR-217 targets the KRAS in osteosarcoma. Interestingly, miR-217 plays contrasting roles in cancer depending on cancer type (Kato et al., 2009; Zhao et al., 2010). Herein, miR-217 is a tumor suppressor which inhibits cell proliferation and metastasis in osteosarcoma. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Quercetin can suppress osteosarcoma cell growth and metastasis. However, other effects of quercetin on osteosarcoma remain largely unknown. This research aims to evaluate the effects of quercetin in combination with cisplatin as treatment for osteosarcoma and investigate its regulatory mechanism. Cell viability and apoptosis in 143B cell line were determined after treatment with quercetin and/or cisplatin. RT-PCR and Western blot analysis were performed to determine the RNA or protein expression levels. Moreover, transwell assay was used to evaluate metastasis. Furthermore, rescue experiments were performed to investigate the potential regulatory mechanism of the treatment. Results showed that quercetin with concentration that was equal to or greater than 10 μM inhibited 143B proliferation, while 5 μM quercetin enhanced the cisplatin sensitivity of 143B cells. Expression of miR-217 was upregulated after quercetin and/or cisplatin treatment, while its target KRAS was downregulated both at mRNA and protein levels. MiR-217 knockdown led to the loss of enhanced cisplatin sensitivity while miR-217 overexpression showed the opposite effects, indicating that quercetin regulated cisplatin sensitivity by modulating the miR-217-KRAS axis. In conclusion, 5 μM quercetin enhanced the cisplatin sensitivity by modulating the miR-217-KRAS axis. This finding suggests that quercetin may be administered with cisplatin to improve the treatment for osteosarcoma.
    Moleculer Cells 06/2015; 38(7). DOI:10.14348/molcells.2015.0037 · 2.09 Impact Factor
  • Source
    • "For example, TGF-β1 is known to activate the Erk/MAPK [10,11] pathway and the phosphoinositide 3-kinase (PI3K)/Akt [12,13,14,15] pathway. These non-Smad pathways work independently or together with Smad complexes to regulate TGF-β1’s functions [7,8,10,11,12,13,14]. For example, activation of Akt signaling by TGF-β1 is shown to promote cell proliferation [16,17,18]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Precartilaginous stem cells (PSCs) could self-renew or differentiate into chondrocytes to promote bone growth. In the current study, we aim to understand the role of transforming growth factor-β1 (TGF-β1) in precartilaginous stem cell (PSC) proliferation, and to study the underlying mechanisms. We successfully purified and primary-cultured PSCs from the neonate mice' perichondrial mesenchyme, and their phenotype was confirmed by the PSC marker fibroblast growth factor receptor-3 (FGFR-3) overexpression. We found that TGF-β1 induced Akt-glycogen synthase kinase-3β (GSK3β) phosphorylation and β-catenin nuclear translocation in the mouse PSCs, which was almost blocked by TGF-β receptor-II (TGFRII) shRNA knockdown. Further, perifosine and MK-2206, two Akt-specific inhibitors, suppressed TGF-β1-induced GSK3β phosphorylation and β-catenin nuclear translocation. Akt inhibitors, as well as β-catenin shRNA knockdown largely inhibited TGF-β1-stimulated cyclin D1/c-myc gene transcription and mouse PSC proliferation. Based on these results, we suggest that TGF-β1 induces Akt activation to promote β-catenin nuclear accumulation, which then regulates cyclin D1/c-myc gene transcription to eventually promote mouse PSC proliferation.
    International Journal of Molecular Sciences 07/2014; 15(7):12665-12676. DOI:10.3390/ijms150712665 · 2.86 Impact Factor
  • Source
    • "Angiotensin II is able to induce TGF-β1; all intracellular signaling activated by glucose entering the cell is able to increase transcription of this profibrogenic cytokine. TGF-β1 can influence the concentration of small, noncoding, single-stranded RNA molecules called microRNAs (miRNAs) in the tubular compartment, as well as at the glomerular level.42,43 These miRNAs, which are synthesized from longer precursors, through a multistep maturation process, act as translational repressors of specific target mRNAs.44 "
    [Show abstract] [Hide abstract]
    ABSTRACT: Diabetes mellitus is the major cause of end stage renal disease (ESRD). We cannot predict which patient will be affected. ESRD patients suffer an extremely high mortality rate, due to a very high incidence of cardiovascular disease. Several randomized, prospective studies have been conducted to quantify the impact of strict glycemic control on morbidity and mortality, and have consistently demonstrated an association between strict glycemic control and a reduction in ESRD. Within the past 20 years, despite the implementation of treatments that were presumed to be renoprotective, diabetes mellitus has continued to rank as the leading cause of ESRD, which clearly indicates that we are still far from understanding the mechanisms involved in the initiation of ESRD. Progressive albuminuria has been considered as the sine qua non of diabetic nephropathy, but we know now that progression to diabetic nephropathy may well happen in the absence of initial microalbuminuria. The search for new biomarkers of early kidney damage has received increasing interest, since early identification of the pathways leading to kidney damage may allow us to adopt measures to prevent the development of ESRD. Most of these biomarkers are deeply influenced by environment, genetics, sex differences, and so on, making it extremely difficult to identify the ideal biomarker to target. At present, there are no new drugs that come close to providing the solutions we desire for our patients (ie, reducing complications). Even when used in combination with standard care, renal complications are, at best, only modestly reduced, at the considerable expense of additional pill burden and exposure to serious off-target effects. In this review, some of the hypothesized mechanisms of this heterogeneous disease will be considered, with particular attention to the tubule-interstitial compartment.
    International Journal of Nephrology and Renovascular Disease 03/2014; 7:107-115. DOI:10.2147/IJNRD.S37883
Show more